Chicago, United States: Global Healthcare Nanotechnology (Nanomedicine) Market Report 2021, Forecast to 2026, The report focuses on encompassing several factors such as global distribution, manufacturers, and various regions. The report has summed up industry analysis size, share, application, and statistics associated with the global Peptide Synthesis market. The report delivers an in-depth competitive landscape, Growth opportunities, market share coupled with product type and applications. The report also estimates comprehensive market revenue along with Growth patterns, and the overall volume of the market.

Crucial information and forecast statistics covered in the Healthcare Nanotechnology (Nanomedicine) Market report will arm both existing and emerging market players with necessary insights to craft long-term strategies as well as maintain business continuity during a crisis such as the ongoing COVID-19 pandemic.

Key players covered in the report include:Amgen, Teva Pharmaceuticals, Abbott, UCB, Roche, Celgene, Sanofi, Merck & Co, Biogen, Stryker, Gilead Sciences, Pfizer, 3M Company, Johnson & Johnson, SmitH& Nephew, Leadiant Biosciences, Kyowa Hakko Kirin, Takeda, Ipsen, Endo International,

Request for Sample Report (Including COVID19 Impact Analysis, full TOC, Tables and Figures) of Healthcare Nanotechnology (Nanomedicine) Market @ https://www.reporthive.com/request_sample/2411789

NOTE: Due to the pandemic, we have included a special section on the Impact of COVID 19 on the Healthcare Nanotechnology (Nanomedicine) Market which would mention How the Covid-19 is affecting the Healthcare Nanotechnology (Nanomedicine) Industry, Market Trends and Potential Opportunities in the COVID-19 Landscape, Covid-19 Impact on Key Regions and Proposal for Healthcare Nanotechnology (Nanomedicine) Players to Combat Covid-19 Impact.Valuable information covered in the Healthcare Nanotechnology (Nanomedicine) Market report has been segregated into key segments and sub-segments.

By Service typeNanomedicineNano Medical DevicesNano Diagnosis

By End useAnticancerCNS ProductAnti-infective

Healthcare Nanotechnology (Nanomedicine) Market: Competition Analysis

The Report Hive Research study presents a comprehensive analysis of global, regional, and country-level players active in the Healthcare Nanotechnology (Nanomedicine) Market. Competitive information detailed in the Healthcare Nanotechnology (Nanomedicine) Market report has been based on innovative product launches, distribution channels, local networks, industrial penetration, production methods, and revenue generation of each market player.

Important Questions Answered in the Healthcare Nanotechnology (Nanomedicine) Market Report

Key Offerings of the Report

>>>>Get Full Customize Report @ https://www.reporthive.com/request_customization/2411789The report firstly introduced the Healthcare Nanotechnology (Nanomedicine) basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the worlds main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

Why Go For Report Hive Research?

Report Hive Research delivers strategic market research reports, statistical surveys, industry analysis and forecast data on products and services, markets and companies. Our clientele ranges mix of global business leaders, government organizations, SMEs, individuals and Start-ups, top management consulting firms, universities, etc. Our library of 700,000 + reports targets high Growth emerging markets in the USA, Europe Middle East, Africa, Asia Pacific covering industries like IT, Telecom, Semiconductor, Chemical, Healthcare, Pharmaceutical, Energy and Power, Manufacturing, Automotive and Transportation, Food and Beverages, etc. This large collection of insightful reports assists clients to stay ahead of time and competition. We help in business decision-making on aspects such as market entry strategies, market sizing, market share analysis, sales and revenue, technology trends, competitive analysis, product portfolio, and application analysis, etc.

Get in Touch with Us :

Report Hive Research

500, North Michigan Avenue,

Suite 6014,

Chicago, IL 60611,

United States

Website: : https://www.reporthive.com

Email: [emailprotected]

Read the original here:
Healthcare Nanotechnology (Nanomedicine) Market Report Global Industry Size, Segment By Key Companies, Types & Applications And Forecast To 2025 |...

DGAP-News: MagForce AG / Key word(s): Half Year Results30.10.2020 / 08:30 The issuer is solely responsible for the content of this announcement.

MagForce AG Publishes Financial Results for the First Half of 2020 and Operative Highlights

- Very significant increase in European patient inquiries for NanoTherm therapy system for the treatment of glioblastomas

- U.S. focal prostate cancer treatment study: positive findings of Stage 1 confirmed during current Stage - positive treatment results also with the streamlined procedure

- Flexible commercialization models for focal cancer treatment centers in the U.S. in place

Berlin, Germany and Nevada, USA, October 30, 2020 - MagForce AG (Frankfurt, Scale, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, published today its financial results for the first half of 2020, ending on June 30, 2020, and operative highlights.

"During the first half of 2020, we have continued to pass several major milestones and have made significant progress both in Europe with our roll-out strategy and the U.S. with the start of the next stage in our pivotal clinical study for the focal ablation of intermediate risk prostate cancer. MagForce continues to cope with the ever-evolving situation around COVID-19, nevertheless I am steadfast in my belief that by pursuing a strategy of expansion with sustainable partnerships in Europe and providing NanoTherm therapy in the U.S. to patients suffering from prostate cancer, MagForce is well positioned for the future." commented Ben Lipps, CEO of MagForce AG and MagForce USA, Inc. "At the same time, MagForce today is in a better operational position than ever before in the company's history - the number of brain tumor treatments in Europe is increasing significantly and sustainably, the interest of clinics is really high, and in the U.S. our pivotal study for the focal treatment of prostate cancer proves that our therapy is achieving the very good treatment results we had hoped for."

Operative Highlights

Europe - Brain Cancer Treatment

In the first half of 2020 we received a very significant increase in patient inquiries for NanoTherm therapy - a strong indication of how convinced MagForce's partner clinics are of the therapeutic option and its use for the treatment of glioblastomas. It can be assumed that the number of treatments will continue to increase sustainably. The global opportunity for treating glioblastoma is approximately 160,000 patients per year - indicating that this procedure has a significant global market opportunity of approximately four billion Euros per year for this treatment.

All company activities in Europe are aimed at further increasing awareness of the NanoTherm therapy system and making it available to patients. For example, the MagForce's 'NanoTherm Therapy School', a practice-oriented, unique and versatile application training course for the use of the NanoTherm therapy system for the treatment of glioblastoma, continues to be very successful. The goal of the comprehensive application training is to certify surgeons in the use of our innovative NanoTherm technology. Just this month, the third session, Module B - Part II, in the training was concluded. As seen in the registration numbers and also in participant feedback, interest in MagForce's innovative therapy is greater than ever before.

As part of the Company's European roll-out strategy, further installations of NanoActivator devices in partner hospitals in Spain and Italy are planned. The opening of these additional centers, which were planned for the second half of 2020, will be further delayed due to the enormous impact that the COVID-19 pandemic is unfortunately currently having again in these countries. However, interest from other European countries has been seen and MagForce will continue its roll-out strategy in the coming months. In addition, in Germany, the official opening of the latest NanoTherm therapy center at the Hufeland clinic in Mhlhausen is scheduled for November and, MagForce is planning another NanoTherm treatment center in Germany. All this will help us to achieve the treatment goal for 2021 and triple the number of commercial treatments compared to 2020.

Commercial Model for Brain Cancer Treatments in Europe: 'Plug-and-Treat'

To make the NanoTherm therapy system more assessable to clinics, MagForce has developed a container 'plug-and-treat' solution, which has become the delivery standard in Germany as well as in European countries. The pre-installed containers only require a dedicated outdoor space and a standard three phase current connection and are transported to the clinic by truck. MagForce delivers complete regulatory and technical documentation to the clinic administration in advance so that official approvals can be issued quickly. With this mobile 'plug-and-treat' solution the Company has been able to significantly shorten the time to start patient treatment in new centers. Currently, no more than three months from the date of order placement to commission a new NanoTherm treatment center in Germany or other European countries is expected. MagForce currently still has materials in stock for the new production of three additional devices, which will be manufactured on schedule, if required.

USA - Focal Prostate Cancer Treatment

Mirroring results on the first stage of the focal prostate cancer treatment study, treatment results in the current stage of the study, with the streamlined procedure, show only minimal treatment-related side effects that are tolerable and similar to those of biopsies. The ablation analysis showed a very well-defined ablation and cell death in the area of the nanoparticle depot, as observed in previous preclinical studies. This was expected, but is nevertheless very encouraging, as patients can be treated much faster. It is obvious that the streamlined study protocol will benefit patients by completing the entire treatment within one day, thus minimizing the burden of repeated visits to the treating physician.

We continue to expect to generate sufficient data in the fourth quarter of 2020 to confirm that our streamlined procedure has minimal side effects for patients and to gain the necessary 80 percent confidence to meet the clinical objectives needed for FDA approval. The big challenges that the COVID-19 pandemic poses to the health care system mean for our study, among other things, that for several weeks now every patient has to be tested, undergo a two-week quarantine and then be tested again. This brings an unavoidable delay to the almost completed current Stage 2a of the study, and by now we expect to complete the current stage still this year and start the final Stage 2b in January.

Commercial Model for Focal Cancer Treatment Centers in the U.S.: Lease Back Partnership

While completing the study, MagForce will begin preparations for commercialization, which is still expected to start in mid or second half of 2021. Our three MagForce USA owned and operated locations in San Antonio, Texas; Seattle, Washington; and Sarasota, Florida will be our primary locations. All three participating clinical trial sites are already fully equipped with the NanoActivator devices, a dedicated and trained staff, and would be in a position to start commercial treatments immediately. Upon completion of the study, the Company plans to have two additional proprietary treatment centers in place. Additional sites will then be opened in strategic locations in the U.S. to enable the treatment of patients locally. MagForce is already in contact with the most important "Active Surveillance Programs" throughout the country to evaluate their desire for an ambulatory NanoActivator.

MagForce USA's commercial model considers two marketing channels: 1) stand-alone Focal Cancer Treatment Centers owned and staffed by MagForce USA. This would allow MagForce USA to bill for the entire procedure as it is standard with for example dialysis treatments; 2) placement of ambulatory NanoActivators in urology clinics, providing the NanoTherm therapy system to the respective clinical site. To facilitate either channel, MagForce USA has established a sale and lease back partnership for U.S. NanoActivators with three-year term each. This will allow MagForce USA to accelerate its commercial plan.

Considering the potential global market, over 500,000 prostate cancer patients could be treated per year and benefit from an effective focal treatment with minimal side effects. The market potential would lie between 3.5 and 12.5 billion USD per year depending on the business model.

Results of operations, net assets and financial position

Revenues amounted to EUR 384 thousand, a strong increase compared to EUR 26 thousand in the previous year. The revenues were generated from the commercial treatment of patients with NanoTherm therapy in Germany in the amount of EUR 212 thousand (previous year: EUR 23 thousand) and NanoTherm and catheter deliveries to subsidiaries in the amount of EUR 173 thousand (previous year: EUR 3 thousand). A total of 11 patients were treated at the German centers and 6 patients in Lublin, Poland in the first half of 2020.

Other own work capitalized amounting to EUR 196 thousand (previous year: EUR 0 thousand) relates to capitalized expenses for preparing the product files for MagForce AG's medical products in accordance with the requirements of the new Medical Device Regulation (MDR).

Other operating income amounted to EUR 332 thousand in the reporting period and was largely at the previous year's level (EUR 329 thousand).

Cost of materials increased from EUR 194 thousand to EUR 286 thousand. The cost of raw materials, supplies and purchased goods as well as purchased services increased to the same extent.

Personnel expenses increased to EUR 2,097 thousand (previous year: EUR 1,846 thousand).

At EUR 1,667 thousand, other operating expenses were EUR 59 thousand higher than in the previous year (EUR 1,608 thousand) and were thus largely at the previous year's level.

The operating result for the first half of 2020 was EUR -3,432 thousand (previous year: EUR -3,610 thousand). The strong increase in revenues contributed significantly to the improved result.

While interest income remained constant at EUR 108 thousand (previous year: EUR 108 thousand), interest expenses rose from EUR 949 thousand to EUR 1,030 thousand due to the expansion of external financing. Write-downs on financial assets increased by EUR 61 thousand and amounted to EUR 521 thousand (previous year: EUR 460 thousand) which relates to the contributions made to finance the operating activities of the subsidiary MT MedTech Engineering GmbH.

The first half of 2020 closed with a net loss of EUR -4,877 thousand. Due to the increased revenues, the result for the period improved by EUR 35 thousand compared to the previous year (EUR -4,912 thousand).

Cash flow from operating activities amounted to EUR -2,290 thousand (previous year: EUR -2,856 thousand). The cash outflow from operating activities was derived indirectly from the net loss for the period. The cash outflows mainly relate to the financing of operating activities.

Cash flow from investing activities amounted to EUR -1,850 thousand (previous year: EUR -785 thousand) and primarily related to the contributions made to provide financial support to the subsidiary MT MedTech Engineering GmbH and payments for the construction of mobile NanoActivators as well as the expenses incurred in preparing the technical documentation for MagForce products.

Cash flow from financing activities amounted to EUR 5,653 thousand (previous year: EUR 3,325 thousand) and is mainly attributable to the payments received in connection with the external financing measures implemented. The payments received were in part offset by cash outflows in the form of interest payments.

At the end of the reporting period, the freely available liquidity amounted to EUR 1,680 thousand (December 31, 2019: EUR 167 thousand). The increase is due to the drawing of the second tranche of the EIB loan and the issue of new convertible bonds.

Outlook and financial prognosis 2020 and beyond

The outlook for the year 2020, as reported in the 2019 annual report, published on June 30, 2020 was reaffirmed by management.

About MagForce AG and MagForce USA, Inc.MagForce AG, listed in the Scale segment of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles. NanoTherm(R), NanoPlan(R), and NanoActivator(R) are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries.

For more information, please visit: http://www.magforce.comGet to know our Technology: video (You Tube)Stay informed and subscribe to our mailing list

Disclaimer

This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.

T +49-30-308380-77E-Mail: bfrankenberg@magforce.com

30.10.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at http://www.dgap.de

Continue reading here:
MagForce AG Publishes Financial Results for the First Half of 2020 and Operative Highlights - PharmiWeb.com

Betina Brresen,1 Anders Elias Hansen,2,3 Frederikke Petrine Fliedner,2 Jonas Rosager Henriksen,3 Dennis Ringkjbing Elema,3,4 Malene Brandt-Larsen,5 Lotte Kellemann Kristensen,2 6 Annemarie Thuri Kristensen,1 6 Thomas Lars Andresen,3 Andreas Kjr2,5

1Department of Veterinary Clinical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Frederiksberg C 1870, Denmark; 2Cluster for Molecular Imaging, Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen N 2200, Denmark; 3DTU Health Technology, Center for Nanomedicine and Theranostics, Technical University of Denmark, Lyngby, Kgs 2800, Denmark; 4DTU Health Technology, The Hevesy Laboratory, Center for Nuclear Technologies, Technical University of Denmark, Roskilde, 4000, Denmark; 5Department of Clinical Physiology, Nuclear Medicine and PET, Copenhagen University Hospital, Copenhagen 2100, Denmark; 6Minerva Imaging, Copenhagen N 2200, Denmark

Correspondence: Andreas KjrCluster for Molecular Imaging, Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3, Copenhagen N 2200, DenmarkTel +45 35 32 75 04Fax +45 35 32 75 46Email akjaer@sund.ku.dk

Background: The accumulation of liposome encapsulated chemotherapy in solid cancers is dependent on the presence of the enhanced permeability and retention (EPR) effect. Positron emission tomography (PET) imaging with a liposome encapsulated radioisotope, such as liposome encapsulated Cu-64 (64Cu-liposome) may help to identify tumors with high liposome accumulation, and thereby stratify patients based on expected benefit from liposomal chemotherapy. However, intravenous administration of liposomes without a cytotoxic content is complicated by the accelerated blood clearance (ABC) phenomenon for succeeding therapeutic liposome dosing. Alternative markers for assessing the tumors EPR level are therefore warranted.Materials and Methods: To increase our understanding of EPR variations and to ultimately identify an alternative marker for the EPR effect, we investigated the correlation between 64Cu-liposome PET/CT (EPR effect) and 68Ga-RGD PET/CT (neoangiogenesis), 18F-FDG PET/CT (glycolysis), diffusion-weighted MRI (diffusivity) and interstitial fluid pressure in two experimental cancer models (CT26 and COLO 205).Results: 64Cu-liposome and 68Ga-RGD SUVmax displayed a significant moderate correlation, however, none of the other parameters evaluated displayed significant correlations. These results indicate that differences in neoangiogenesis may explain some EPR variability, however, as correlations were only moderate and not observed for SUVmean, 68Ga-RGD is probably insufficient to serve as a stand-alone surrogate marker for quantifying the EPR effect and stratifying patients.

Keywords: EPR effect, liposome, positron emission tomography, neoangiogenesis

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

See the article here:
Noninvasive Molecular Imaging of the Enhanced Permeability and Retenti | IJN - Dove Medical Press

TAMPA, Fla., Oct. 28, 2020 /PRNewswire/ -- The National Academy of Inventors (NAI) has released its sixth video documenting the path from university discovery to public marketplace. This episode in the From Campus to Commerceseries highlights silver nanoparticle technology from the University of Missouri (Mizzou) developed by Dr. Kattesh Katti.

Katti is the recipient of the Hevesy Medal, a highly regarded award in Nuclear Sciences and Medicine. He is also globally known as the "Father of Green Medical Nanotechnology" for his pioneering work combining non-toxic nanoagents with traditional Ayurvedic-Holistic Medicine, used by 65-80 percent of the world's population as a primary source of health care.

In the video, Katti is seen in his lab discussing the impetus for his chosen work. "I wanted to create one product with dual actions of antibiotic/anti-viral properties so that people don't have to use several different agents to decontaminate infected areas."

His discoveries have been enormously successful, especially the timely product NanOLife sanitizer, which kills BOTH bacteria and viruses, including COVID-19.

Over the past three decades, Katti's work has also focused on molecular imaging and therapy in oncology. His gold-based nanomedicine is being used in cancer therapy today. In an NAI webinarearlier this month, he explained that gold, unlike many delivery mechanisms, is non-toxic to the body.

Katti has been recognized by the United Nations/IAEA as the Global Expert in 'Green Nanotechnology' and has won many awards such as the 2016 Person of the Year in Science. He is a Fellow of the National Academy of Inventors as well as a professor at Mizzou.

More information about Dr. Katti's work can be found on his website.

Watch all of the From Campus to Commerce videoson NAI's YouTube channel and check out the Academy's new ScholarShare webinar seriesas well.

About the National Academy of Inventors

The National Academy of Inventorsis a member organization comprising U.S. and international universities, and governmental and non-profit research institutes, with over 4,000 individual inventor members and Fellows spanning more than 250 institutions worldwide. It was founded in 2010 to recognize and encourage inventors with patents issued from the U.S. Patent and Trademark Office (USPTO), enhance the visibility of academic technology and innovation, encourage the disclosure of intellectual property, educate and mentor innovative students, and translate the inventions of its members to benefit society. The NAI works collaboratively with the USPTO and publishes the multidisciplinary journal, Technology and Innovation. http://www.academyofinventors.org.

Media Contact: Jody Santoro[emailprotected]1-813-974-0782

SOURCE National Academy of Inventors

http://www.academyofinventors.org/

Link:
"Father of Green Medical Nanotechnology" Featured in the Latest Episode of From Campus to Commerce - PRNewswire

Swansea University Medical Schools Professor Steve Conlan has taken up a key role helping to highlight UK nanomedicine research.

He has been appointed Chair of the British Society for Nanomedicine (BSNM), the UKs leading organisation which seeks to give industry, academia, clinicians and the public access to news of ongoing nanomedicine research throughout the UK.

Professor Conlan, who is the Medical Schools head of enterprise and innovation, explained that the field of nanomedicine the application of nanotechnology to healthcare is still relatively new, but its global benefits are multiplying every year, with 50 nanomedicines already in clinical trials.

He said: Nanomedicine is a growing and diverse area of research providing new and innovative treatments that are benefiting patients on a global scale.

Here at Swansea we have access to cutting-edge technology teamed with world leading researchers and teachers in the field. Through BSNM we will be able to promote and share research ideas and form new collaborations that will benefit the nanomedicine community and aid in the development of much-needed diagnostics and therapeutics.

BSNM aims to explain ongoing science and commercial developments so the public can understand and stay in touch with this exciting area as it impacts future healthcare.

Professor Conlan will share the post with co-chair Dr Tom McDonald, from the University of Liverpool.

One of their first responsibilities is to host a series of online early career researcher events to build on the success of annual events held around the UK over the past 10 years.

The first of these take place on November 25 and 26 and will provide an opportunity for ECRs to showcase innovative research and discuss outputs and opportunities with other researchers and experts in the field of nanomedicine.

It will also offer researchers the chance to network and collaborate with the wider nanomedicine community during interactive breakout sessions.

Junior researchers (PhDs and Post-docs) can share their work through a 15-minute presentation. Anyone interested in taking part should contact [emailprotected] no later than Friday, October 30.

The free event will be held on Zoom and those interested can register to attend via Eventbrite, or at BSNM.

View original post here:
Professor's new role helping to promote nanomedicine across the UK - Wales247

Regulatory News:

NANOBIOTIX (Paris:NANO) (Euronext: NANO ISIN: FR0011341205 the Company), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that the first patient has been injected in its phase I study evaluating NBTXR3 activated by radiation therapy for patients with pancreatic cancer. The trial is a being conducted at The University of Texas MD Anderson Cancer Center (MD Anderson) as part of an ongoing clinical collaboration.

Two additional trials from the clinical collaboration received safe to proceed notifications from the United States Food and Drug Administration (FDA): (i) a phase I study evaluating NBTXR3 activated by radiation therapy for patients with lung cancer amenable to re-irradiation; and (ii) a phase I study evaluating NBTXR3 activated by radiation therapy with concurrent chemotherapy for patients with esophageal cancer. All current and future trials in this clinical collaboration are sponsored and executed by MD Anderson.

A Phase I Study Evaluating NBTXR3 Activated by Radiation Therapy in Patients with Pancreatic Cancer

Pancreatic cancer is a rare, deadly disease that accounts for approximately 3% of all cancers and has a 5-year survival rate of 9%1.

This pancreatic cancer trial is an open-label, single-arm, prospective phase I study consisting of two parts: (i) dose-escalation to determine the recommended phase 2 dose (RP2D) of NBTXR3 activated by radiation therapy; and (ii) expansion at RP2D.

The patient population will include adults (age 18 years) with borderline resectable pancreatic cancer (BRPC) or locally advanced pancreatic cancer (LAPC) that are radiographically non-metastatic at screening, and that have not previously received radiation therapy or surgery for pancreatic cancer. Up to 24 subjects will be enrolled and the planned enrollment period is 18 months.

The objectives of the study are the determination of dose-limiting toxicity (DLT), the maximum tolerated dose (MTD), and the RP2D.

Two Additional Phase I Studies in Lung and Esophageal Cancer Pending

A phase I trial investigating NBTXR3 activated by radiation therapy for patients with lung cancer amenable to re-irradiation, and a phase I trial investigating NBTXR3 activated by radiation therapy with concurrent chemotherapy for patients with esophageal cancer have been deemed safe to proceed by FDA. Safe to proceed notifications are delivered once the agency is satisfied with the information contained in an investigational new drug application (IND) or any additional information or clarification has been provided.

Lung cancer is the second most common cancer type, and the leading cause of cancer death for both men and women. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, with a 5-year survival rate of 24% worldwide.2

The lung cancer trial is an open-label, two-cohort, prospective phase I study consisting of two parts: (i) a radiation therapy safety lead-in, and NBTXR3 activated by radiation therapy dose-finding to determine the RP2D; and (ii) expansion at the RP2D with toxicity monitoring.

The patient population will include adults (age 18 years) with inoperable, locoregional recurrent (LRR) non-small cell lung cancer (NSCLC) stage IA to IIIC that are radiographically non-metastatic at screening and have previously received definitive radiation therapy. Cohort 1 will evaluate the safety of intensity-modulated radiation therapy (IMRT) monotherapy in 10 patients. Up to 24 subjects will be enrolled in cohort 2. Recruitment is expected to begin in 4Q2020 and the planned enrollment period is 36 months.

Esophageal cancer is the eighth most common cancer type and the sixth most common cause of cancer deaths worldwide. The 5-year survival rate in the US is 20%, and 10% in Europe3.

The esophageal cancer trial is an open-label, single-arm, prospective phase I study consisting of two parts: (i) dose-escalation to determine the RP2D of NBTXR3 activated by radiation therapy with concurrent chemotherapy, as per standard of care; and (ii) expansion at the RP2D with toxicity monitoring.

The patient population will include adults (age 18 years) with stage II-III adenocarcinoma of the esophagus that are treatment nave and radiographically non-metastatic at screening. Up to 24 subjects will be enrolled. Recruitment is expected to begin in 4Q2020 and the planned enrollment period is 24 months.

Next Steps for Clinical Collaboration with MD Anderson

The clinical collaboration between Nanobiotix and MD Anderson includes plans for additional clinical trials across several indications. Beyond the three (3) trials mentioned above, the other trials, including four (4) combination trials with immune checkpoint inhibitors and NBTXR3 activated by radiation therapy, are in preparation and will launch in due time.

***

About NBTXR3

NBTXR3 is a novel radioenhancer composed of functionalized hafnium oxide nanoparticles that is administered via one-time intra-tumoral injection and activated by radiation therapy. The physical and universal mode of action (MoA) of NBTXR3 is designed to trigger cellular destruction death and adaptive immune response.

NBTXR3 is being evaluated in locally advanced head and neck squamous cell carcinoma (HNSCC) of the oral cavity or oropharynx in elderly patients unable to receive chemotherapy or cetuximab with limited therapeutic options. Promising results have been observed in the phase I trial regarding local control. In the United States, the Company has started the regulatory process to commence a phase III clinical trial in locally advanced head and neck cancers. In February 2020, the United States Food and Drug Administration granted the regulatory Fast Track designation for the investigation of NBTXR3 activated by radiation therapy, with or without cetuximab, for the treatment of patients with locally advanced head and neck squamous cell cancer who are not eligible for platinum-based chemotherapy.

Nanobiotix is also running an Immuno-Oncology development program. The Company has launched a Phase I clinical trial of NBTXR3 activated by radiotherapy in combination with anti-PD-1 checkpoint inhibitors in locoregional recurrent (LRR) or recurrent and metastatic (R/M) HNSCC amenable to re-irradiation of the HN and lung or liver metastases (mets) from any primary cancer eligible for anti-PD-1 therapy.

Other ongoing NBTXR3 trials are treating patients with hepatocellular carcinoma (HCC) or liver metastases, locally advanced or unresectable rectal cancer in combination with chemotherapy, head and neck cancer in combination with concurrent chemotherapy, and pancreatic cancer. The Company is also engaged in a broad, comprehensive clinical research collaboration with The University of Texas MD Anderson Cancer Center to further expand the NBTXR3 development program.

About NANOBIOTIX: http://www.nanobiotix.com

Incorporated in 2003, Nanobiotix is a leading, clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.

The Nanobiotix philosophy is rooted in designing pioneering, physical-based approaches to bring highly effective and generalized solutions to address unmet medical needs and challenges.

Nanobiotixs novel, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Nanobiotixs Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies.

Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP). The Companys headquarters are in Paris, France, with a US affiliate in Cambridge, MA, and European affiliates in France, Spain and Germany.

Disclaimer

This press release contains certain forward-looking statements concerning Nanobiotix and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the universal registration document of Nanobiotix registered with the French Financial Markets Authority (Autorit des Marchs Financiers) under number R.20-010 on May 12, 2020 (a copy of which is available on http://www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.

1 https://www.cancer.net/cancer-types/pancreatic-cancer/statistics

2 https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/statistics

3 https://www.cancer.net/cancer-types/esophageal-cancer/statistics

View source version on businesswire.com: https://www.businesswire.com/news/home/20201012005825/en/

NanobiotixCommunications DepartmentBrandon OwensVP, Communications+1 (617) 852-4835

contact@nanobiotix.com

Investor Relations DepartmentRicky BhajunSenior Manager, Investor Relations+33 (0)1 79 97 29 99

investors@nanobiotix.com

Media RelationsFrance Ulysse CommunicationPierre-Louis Germain

+ 33 (0)6 64 79 97 51

plgermain@ulysse-communication.com

The rest is here:
NANOBIOTIX Announces First Patient Injected with NBTXR3 in Pancreatic Cancer and Safe to Proceed Notifications for Two Additional Trials From U.S. FDA...

Given the debilitating impact of COVID-19 (Coronavirus) on the Healthcare Nanotechnology (Nanomedicine) market, companies are vying opportunities to stay afloat in the market landscape. Gain access to our latest research analysis on COVID-19 associated with the Healthcare Nanotechnology (Nanomedicine) market and understand how market players are adopting new strategies to mitigate the impact of the pandemic.

The report provides both quantitative and qualitative information of global Healthcare Nanotechnology (Nanomedicine) market for period of 2018 to 2025. As per the analysis provided in the report, the global market of Healthcare Nanotechnology (Nanomedicine) is estimated to growth at a CAGR of _% during the forecast period 2018 to 2025 and is expected to rise to USD _ million/billion by the end of year 2025. In the year 2016, the global Healthcare Nanotechnology (Nanomedicine) market was valued at USD _ million/billion.

This research report based on Healthcare Nanotechnology (Nanomedicine) market and available with Market Study Report includes latest and upcoming industry trends in addition to the global spectrum of the Healthcare Nanotechnology (Nanomedicine) market that includes numerous regions. Likewise, the report also expands on intricate details pertaining to contributions by key players, demand and supply analysis as well as market share growth of the Healthcare Nanotechnology (Nanomedicine) industry.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/6370

Healthcare Nanotechnology (Nanomedicine) Market Overview:

The Research projects that the Healthcare Nanotechnology (Nanomedicine) market size will grow from in 2018 to by 2024, at an estimated CAGR of XX%. The base year considered for the study is 2018, and the market size is projected from 2018 to 2024.

Leading manufacturers of Healthcare Nanotechnology (Nanomedicine) Market:

Key players in the global nanomedicine market include: Abbott Laboratories, CombiMatrix Corporation, GE Healthcare, Sigma-Tau Pharmaceuticals, Inc., Johnson & Johnson, Mallinckrodt plc, Merck & Company, Inc., Nanosphere, Inc., Pfizer, Inc., Celgene Corporation, Teva Pharmaceutical Industries Ltd., and UCB (Union chimique belge) S.A.

Key geographies evaluated in this report are:

Key features of this report

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/6370

Some important highlights from the report include:

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/6370

The Questions Answered by Healthcare Nanotechnology (Nanomedicine) Market Report:

And Many More.

Read the rest here:
R&D Activities to Fast-track the Growth of the Healthcare Nanotechnology (Nanomedicine) Market Between 2015 2021 - PRnews Leader

(Sep, 2020) United Kingdom, The report titled Nanorobots Market: Size, Trends and Forecasts (2020-2026), delivers an in-depth analysis of the Nanorobots Industry by considering there type, application, market value, by production capacity, by companies, by region, etc.

The report assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the Nanorobotsindustry. Growth of the overall Nanorobotsmarket has also been forecasted for the period 2020-2026, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.

Get Exclusive Sample copy on Nanorobots Marketis available athttps://www.worldwidemarketreports.com/sample/366582

NanorobotsMarket report analyses the impact of Coronavirus (COVID-19) on theNanorobotsindustry.

Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; emergency declared in many countries; massive slowing of the supply chain; stock market unpredictability; falling business assurance, growing panic among the population, and uncertainty about future.

COVID-19 can affect the global economy in 3 main ways: by directly affecting production and demand, by creating supply chain and market disturbance, and by its financial impact on firms and financial markets.

If you are investor/shareholder in theNanorobotsMarket, the provided study will help you to understand the growth model ofNanorobotsIndustry after impact of COVID-19. Request for sample report (including ToC, Tables and Figures with detailed information) @https://www.worldwidemarketreports.com/covidimpact/366582

The research report segments the market from a relevancy perspective into the below segments and sub-segments with the quantitative analysis done from 2017 to 2026 considering 2019 as the base year for the research. Compounded Annual Growth Rate (CAGR) for each respective segment and sub-segment is calculated for the forecast period from 2019 to 2026 to provide a reference for growth potential.

Nanorobotsmarket segmented on the basis of Product Type:Nanomanipulator, Bio-Nanorobotics, Magnetically Guided, Bacteria-Based

Nanorobotsmarket segmented on the basis of Application: Nanomedicine, Biomedical, Others

The major players profiled in this report include:Bruker, Jeol, Thermo Fisher, Ginkgo Bioworks, Oxford Instruments, Ev Group, Imina Technologies, Toronto Nano Instrumentation, Klocke Nanotechnik, Kleindiek Nanotechnik, Xidex, Synthace, Park Systems, Smaract, Nanonics Imaging, Novascan Technologies, Angstrom Advanced, Hummingbird Scientific, Nt-Mdt Spectrum Instruments, Witec

Get Chance of 20% Extra Discount, If your Company is Listed in Above Key Players List;https://www.worldwidemarketreports.com/discount/366582

Regional Coverage of theNanorobotsMarket:

Reasons to PurchaseNanorobotsMarket Research Report

:DOWNLOAD COMPLETE PDF BROCHURE:

Contact Us:

Mr. ShahWorldwide Market ReportsSeattle, WA 98154,U.S.Email: [emailprotected]

Follow this link:
Mobile Nanorobots Market Size, Share & Trends Analysis Report By Product Types, And Applications Forecast To 2026: Bruker, Jeol, Thermo Fisher,...

Nanomedicine Market Report Delivering Growth Analysis with Key Trends of Top Companies (2020-2026)

A comprehensive research study on the Nanomedicine Marketwas recently published by Market Report Expert. This is an up-to-date report, covering the current COVID-19 impact on the market. The Coronavirus (COVID-19) has affected every aspect of life globally and thus altering the global market scenario. The changes in the market conditions are drastic. The swiftly changing market scenario and initial and future assessment of the impact on Nanomedicine market is covered in the report.The Nanomedicine Market report is a precise and deep-dive study on the current state that aims at the major drivers, market strategies, and imposing growth of the key players. Worldwide Nanomedicine Industry also offers a granular study of the dynamics, segmentation, revenue, share forecasts, and allows you to make superior business decisions. The report serves imperative statistics on the market stature of the prominent manufacturers and is an important source of guidance and advice for companies and individuals involved in the Nanomedicine industry.

The Global Nanomedicine Market poised to grow from US$ XX million in 2020 to US$ XX million by 2026 at a compound annual growth rate (CAGR) of XX% during the projection period of 2020-2026.

An Outline of the Major Key Players covered in this Report:

Combimatrix, Ablynx, Abraxis Bioscience, Celgene, Mallinckrodt, Arrowhead Research, GE Healthcare, Merck, Pfizer, Nanosphere, Epeius Biotechnologies, Cytimmune Sciences, Nanospectra Biosciences

Get Free LatestPDF Template of this Report(Including Covid-19 impact analysis on overall industry Forecast, Size, Share, CAGR and more.)@ https://www.marketreportexpert.com/report/Nanomedicine/13084/sample

Note: We can also provide market report in German/French Language.

The report puts together a succinct analysis of the growth drivers influencing the current business scenario across various regions and countries. Substantial information pertaining to the industry analysis size, share, application, and statistics are summed in the report in order to present a collaborative prediction. Additionally, this report encompasses a precise competitive analysis of major market players, innovative companies, and their strategies during the projection timeline.

The latest report on the Nanomedicine Market consists of an analysis of this industry and its type, application, and other segments. As per the report, the market is estimated to gain significant returns and register substantial y-o-y growth during the forecast period of 2020-2026.

Majortype, primarily split into

Quantum dotsNanoparticlesNanoshellsNanotubesNanodevices

Major applications/end users, including

Segmentation encompasses oncologyInfectious diseasesCardiologyOrthopedicsOthers

According to the report, the study offers details regarding the valuable estimations of the market such as market size, sales capacity, and profit projections. The report documents factors such as drivers, restraints, and opportunities that impacts the remuneration of this market.

Feel Free! Ask Our Industry Expert For Discount on this Report(Note: Our reports include the analysis of the impact of COVID-19 on this industry. Our updated sample pages shows impact of Covid-19 on Industry trends. Also we are offering 20% discount.): https://www.marketreportexpert.com/report/Nanomedicine/13084/inquiry

The research offers an analysis of the geographical landscape of the Nanomedicine Market, which is divided into regions such as North America, Europe, Asia Pacific, South America, and the Middle East & Africa. The segment includes data about several parameters related to the regional contribution such as market share, application share, type share, key companies in respective regions, market share of key companies in regional market, growth rate and revenue of the regional market, sales, production, and consumption of the respective Nanomedicine market.

Major Highlights of TOC Covers:

Nanomedicine Market 2020, Nanomedicine Market size, Nanomedicine Market share, Nanomedicine Market analysis, Nanomedicine Market forecast, Nanomedicine Market trends, Nanomedicine Market Research report, Nanomedicine application, Nanomedicine Trends, Nanomedicine Market growing CAGR, Nanomedicine Market Competitive Landscape, Nanomedicine Market Growth

Information related to the growth rate, revenue, sales, production, consumption, during the forecast period is included in the report. The Nanomedicine Market report claims that the industry is projected to generate significant revenue and sales during the forecast period. The report consists of information related to the market dynamics such as challenges involved in this vertical, growth opportunities, and driving factors affecting the market.

About Us

Market Report Expert is a futuristic market intelligence company, helping customers flourish their business strategies and make better decisions using actionable intelligence. With transparent information pool, we meet clients objectives, commitments on high standard and targeting possible prospects for SWOT analysis and market research reports.

Contact USJames ThompsonMarket Report ExpertPhone: +1-816-301-6258Email inquiry@marketreportexpert.comWeb:-https://www.marketreportexpert.com

Read the original:
2020 Trending: Nanomedicine Market is Thriving Worldwide By Size, Revenue, Emerging Trends and Top Growing Companies 2026| Combimatrix, Ablynx,...

Cancer is a complex disease to treat, and yet the operating principle of many current treatments is to simply kill healthy cells a little slower than cancerous ones. In response, scientists at the University of Electronic Science and Technology of China have developed a sophisticated nanoparticle-based treatment. Their theranostic nanoparticles carry an anti-cancer drug cargo, and showcase multiple cutting-edge nanomedicine technologies to enhance the drug's efficacy, including selective drug delivery, photoactive agents, and even signal-jamming genetic material.

The researchers have designed each individual nanoparticle to be a toolbox for cancer therapy, able to passively and actively target tumours (Biomater. Sci. 5 1001). The nanoparticles can act as contrast agents for both magnetic resonance imaging and X-ray, they deliver a concentrated dose of anti-cancer drugs, and they also thwart the cancer's attempts at developing immunity to the drug. They even deliver a photosensitizer that can be used to specifically weaken cancerous tissue by photodynamic treatment.

Yiyao Liu and colleagues demonstrated the efficacy of their nanodevices in vitro and in vivo on a range of cell lines and on tumours in living mice. They found that their nanoparticle drug-delivery technique effectively stopped tumour growth, whereas tumours in mice treated with the drug alone grew at a rate half that of a control group that had not been treated.

The nanoparticles are complex, many layered spheres. Protected by a jacket of natural polymer is a nugget of silica, holey like a sponge and soaked in doxorubicin, a common anti-cancer drug, along with the photosensitizer. The polymer jacket is pH sensitive so that it falls off in the acidic microenvironment of the tumour, only then releasing the active cargo.

Doxorubicin has two flaws. Firstly, it works by slotting in-between DNA base pairs to stop the replication process needed for cells to divide. This kills cells that need to duplicate quickly, such as cancerous cells, but harms many healthy cell types too. Secondly, it triggers the body's natural defences, causing cells to over express p-glycoprotein, a microscale pump that removes toxic molecules like doxorubicin from cells, and making the drug less and less effective against cancer.

The scientists at The University of Electronic Science and Technology of China countered both of these flaws. Healthy cell exposure is reduced by the polymer jacket, which makes sure the drug is only released under the conditions expected in a tumour. The jacket itself is covered in signal-jamming RNA to inhibit the expression of the cellular pumps, keeping the doxorubicin trapped inside the cells to allow the drug to work for longer. This impressive display of multifunctional nanoparticle design and synthesis demonstrates the power of nanomedicine for producing synergistic effects, offering new solutions to previously unsurmountable problems.

Denser nanoparticles boost drug penetration Personalize nanoparticles to target tumours Inhaled nanoparticles target lung cancer Nanoneedles deliver therapeutics into cells

See the original post here:
Nanomedicine enables all-in-one cancer treatment - Medical Physics Web (subscription)

May 24, 2017 by Maria Kavallaris, Joshua Mccarroll And Thomas P Davis, The Conversation Therapies on a nano scale rely on engineered nanoparticles designed to package and deliver drugs to exactly where theyre needed. Credit: shutterstock.com

A recent US study of people treated for cancer as children from the 1970s to 1999 showed that although survival rates have improved over the years, the quality of life for survivors is low. It also showed this was worse for those who were treated in the 1990s.

About 70% of childhood cancer survivors experience side effects from their treatment, including secondary cancers. And as survival rates improve, the worldwide population of childhood cancer survivors is growing.

Side effects cause stress for survivors and families and increase demand on health systems. But an emerging area of medicine, nanomedicine, offers hope for better children's cancer treatment that will have fewer side effects and improve quality of life for survivors.

What is nanomedicine?

Nanomedicine is the application of nanomaterials, or nanoparticles, to medicine. Nanoparticles are a form of transport for drugs and can go places drugs wouldn't be able to go on their own.

Nano means tiny. A nanometre (nm) is one-billionth of a metre. Nanoparticles used for drug delivery are usually in the 20 to 100 nanometre range, although this can vary depending on the design of the nanoparticle.

Nanoparticles can be engineered and designed to package and transport drugs directly to where they're needed. This targeted approach means the drugs cause most harm in the particular, and intended, area of the tumour they are delivered to. This minimises collateral damage to surrounding healthy tissues, and therefore the side effects.

The first cancer nanomedicine approved by the US Food and Drug Administration was Doxil. Since 1995, it has been used to treat adult cancers including ovarian cancer, multiple myeloma and Karposi's sarcoma (a rare cancer that often affects people with immune deficiency such as HIV and AIDS).

Currently, there is a stream of new nanomedicine treatments for adult cancers in clinical trials (trials in humans), or on the market. But only a limited number of these have been approved for children's cancers, although this is arguably where nanomedicine's strengths could have the most benefit.

How does nanomedicine work?

The nanoparticle drug-delivery systems can work in different ways. Along with carrying the drug for delivery, nanoparticles can be engineered to carry specific compounds that will let them bind, or attach, to molecules on tumour cells. Once attached, they can safety deliver the drug to the specific tumour site.

Nanoparticles can also help with drug solubility. For a drug to work, it must be able to enter the bloodstream, which means it needs to be soluble. For example, the cancer drug paclitaxel (Taxol) is insoluble so has to be dissolved in a delivery agent to get into the blood. But this agent can cause allergic reactions in patients.

To overcome these issues, chemists have developed a nanoparticle out of the naturally occurring protein albumin. It carries the paclitaxel and makes it soluble but without the allergic reactions.

Tumours commonly have disordered and leaky blood vessels sprouting through and off them. These vessels allow chemotherapy drugs to readily enter the tumour, but because chemotherapy molecules are so small, they also diffuse through the vessels and out of the tumour, attacking surrounding tissues. Nanoparticles are larger molecules that get trapped inside the tumour, where they do all the damage.

Once they have delivered their drug cargo to cells, nanoparticles can be designed to break down into harmless byproducts. This is particularly important for children who are still developing.

Types of nanoparticles

Nanoparticles vary in characteristics like shape and size. Researchers need to match the right nanoparticle to the drug it's to deliver and the particular tumour.

An array of nanoparticle structures are currently being engineered. One example of an interesting structure is the shape of a DNA origami. Because DNA is a biological material, nanoparticles engineered into DNA origami shapes won't be seen as foreign by the immune system. So these can transport a drug to diseased cells while evading the body's immune system, therefore lessening the side effects of drugs.

Another example of nanomedicine structures are polymeric nanocarriers. We have recently identified a gene that promotes the growth of tumours, cancer spread and resistance to chemotherapy in pancreatic cancers.

We used a nanomedicine called a polymeric nanocarrier and combined it with a drug that silences the cancer gene. We packaged this up to form a nanomedicine and delivered the drugs into the tumour.

These nanomedicines reduced the expression of the cancer gene, blocked tumour growth and reduced the spread of pancreatic cancer. But we also showed that polymeric nanocarriers can be combined in the lab with other gene-silencing drugs. This means the method can be used for a range of other gene-based cancers.

How can nanomedicines help treat kids' cancer?

In standard treatment for children's cancer, chemotherapy drugs are often prescribed at the maximum tolerable dose for a child's age or size, based on adult dosages. But children aren't small adults. The processes underlying children's growth and development might lead to a different effect and response to a chemotherapy drug not seen in adults.

Also, if a child becomes resistant to a drug and they're on the maximum tolerable dose, there's no scope to increase it without toxic side effects. By packaging up drugs and moving them through the body directly to diseased cells to reduce collateral damage, in theory, nanomedicine allows higher doses of drugs to be used.

Nanomedicine has great potential to safely treat children's cancer. However, it is currently stymied by too little research. About two-thirds of research attention in nanomedicine therapeutics, of more 250 nanomedicine products, is focused on cancer. Yet this isn't translating into new cancer treatments for children coming to market.

But we are making progress. Our work is exploring the design of nanoparticles to deliver gene-silencing drugs to treat the most common brain cancer in children medulloblastoma.

We're also working on nanomedicines for other significant childhood cancers. These include drug-refractory acute lymphoblastic leukaemia, the most common childhood cancer, and neuroblastoma, the cancer that claims more lives of those under five than any other.

Explore further: New nanotechnology application for difficult-to-treat cancers

This article was originally published on The Conversation. Read the original article.

A new treatment combining shock waves with nanoparticles can successfully treat tumours that are difficult to target using conventional chemotherapy. This is the first time this combined therapy has been tested in live animals. ...

Australian cancer researchers have developed a highly promising nanomedicine that could improve treatment for pancreatic cancer the most deadly cancer in Australia.

Nanomedicine has the potential to help personalize cancer treatments and reduce side effects of therapeutic drugs. While some progress has been made toward the latter goal, customized treatments are still hard to come by. ...

A Mayo Clinic research team has developed a new type of cancer-fighting nanoparticle aimed at shrinking breast cancer tumors, while also preventing recurrence of the disease. In the study, published today in Nature Nanotechnology, ...

New research carried out by drug delivery experts at The University of Nottingham has highlighted more advantages to using nanoparticles for the delivery of cancer drugs.

Targeting cancer cells for destruction while leaving healthy cells alonethat has been the promise of the emerging field of cancer nanomedicine. But a new meta-analysis from U of T's Institute of Biomaterials & Biomedical ...

In the May issue of PLOS Computational Biology, scientists from UC San Diego and the University of Notre Dame report on a study that could open up the field for nanopore-based protein identification and eventually proteomic ...

Researchers at the University of Central Florida have developed a new color changing surface tunable through electrical voltage - a breakthrough that could lead to three times the resolution for televisions, smartphones and ...

Researchers from North Carolina State University have discovered a technique for controlling light with electric fields.

Dr. Saw-Wai Hla and Dr. Eric Masson are thrilled with their team's performance in the world's first nanocar race in April, but for them, it was a fun starting point to a much larger goal.

Researchers from AMOLF and Swiss EPFL have shown that the surface of minuscule water drops surrounded by a hydrophobic substance such as oil is surprisingly ordered. At room temperature, the surface water molecules of these ...

Computers process and transfer data through electrical currents passing through tiny circuits and wires. As these currents meet with resistance, they create heat that can undermine the efficiency and even the safety of these ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Go here to see the original:
What is nanomedicine, and how can it improve childhood cancer treatment? - Phys.Org

The globalRadiocontrast Agent Marketis carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the global Radiocontrast Agent market. For instance, the market dynamics section digs deep into the drivers, restraints, trends, and opportunities of the global Radiocontrast Agent market. With qualitative and quantitative analysis, we help you with thorough and comprehensive research on the global Radiocontrast Agent market. We have also focused on SWOT, PESTLE, and Porters Five Forces analyses of the global Radiocontrast Agent market.

Leading players of the global Radiocontrast Agent market are analyzed taking into account their market share, recent developments, new product launches, partnerships, mergers or acquisitions, and markets served. We also provide an exhaustive analysis of their product portfolios to explore the products and applications they concentrate on when operating in the global Radiocontrast Agent market. Furthermore, the report offers two separate market forecasts one for the production side and another for the consumption side of the global Radiocontrast Agent market. It also provides useful recommendations for new as well as established players of the global Radiocontrast Agent market.

Request sample copy of this report:https://www.reporthive.com/request_sample/2345748

Major Players:

GE Healthcare (US)Bracco Imaging (Italy)Bayer HealthCare (Germany)Guerbet (France)Lantheus (US)Daiichi Sankyo (Japan)Unijules Life Sciences (India)J.B. Chemicals and Pharmaceuticals (India)Spago Nanomedicine (Sweden)Taejoon Pharm (South Korea)Jodas (India)Magnus Health (India)

Segmentation by Product:

Barium-based Radiocontrast AgentIodinated Radiocontrast AgentGadolinium-based Radiocontrast AgentMicrobubble Radiocontrast AgentX-ray/Computed Tomography (CT)Magnetic Resonance Imaging (MRI)Ultrasound

Segmentation by Application:

RadiologyInterventional RadiologyInterventional Cardiology

Regions and Countries:U.S, Canada, France, Germany, UK, Italy, Rest of Europe, India, China, Japan, Singapore, South Korea, Australia, Rest of APAC, Brazil, Mexico, Argentina, Rest of LATAM, Saudi Arabia, South Africa, UAE.

Report Objectives

Table of Contents

Report Overview:It includes major players of the global Radiocontrast Agent market covered in the research study, research scope, and Market segments by type, market segments by application, years considered for the research study, and objectives of the report.

Global Growth Trends:This section focuses on industry trends where market drivers and top market trends are shed light upon. It also provides growth rates of key producers operating in the global Radiocontrast Agent market. Furthermore, it offers production and capacity analysis where marketing pricing trends, capacity, production, and production value of the global Radiocontrast Agent market are discussed.

Market Share by Manufacturers:Here, the report provides details about revenue by manufacturers, production and capacity by manufacturers, price by manufacturers, expansion plans, mergers and acquisitions, and products, market entry dates, distribution, and market areas of key manufacturers.

Market Size by Type:This section concentrates on product type segments where production value market share, price, and production market share by product type are discussed.

Market Size by Application:Besides an overview of the global Radiocontrast Agent market by application, it gives a study on the consumption in the global Radiocontrast Agent market by application.

Production by Region:Here, the production value growth rate, production growth rate, import and export, and key players of each regional market are provided.

Consumption by Region:This section provides information on the consumption in each regional market studied in the report. The consumption is discussed on the basis of country, application, and product type.

Company Profiles:Almost all leading players of the global Radiocontrast Agent market are profiled in this section. The analysts have provided information about their recent developments in the global Radiocontrast Agent market, products, revenue, production, business, and company.

Market Forecast by Production:The production and production value forecasts included in this section are for the global Radiocontrast Agent market as well as for key regional markets.

Market Forecast by Consumption:The consumption and consumption value forecasts included in this section are for the global Radiocontrast Agent market as well as for key regional markets.

Value Chain and Sales Analysis:It deeply analyzes customers, distributors, sales channels, and value chain of the global Radiocontrast Agent market.

Key Findings:This section gives a quick look at important findings of the research study.

Request for Customization:https://www.reporthive.com/request_customization/2345748

About us:

Our research base consists of a wide spectrum of premium market research reports. Apart from comprehensive syndicated research reports, our in-house team of research analysts leverages excellent research capabilities to deliver highly customized tailor-made reports. The market entry strategies presented in our reports has helped organizations of all sizes to generate profits by making timely business decisions. The research information including market size, sales, revenue, and competitive analysis offered, is the product of our excellence in the market research domain.

Original post:
Impact of Corona on Radiocontrast Agent Market : Which country will show the highest growth? - Owned

DataIntelo report titled Global Nanomedicine Market provides detailed information and overview about the key influential factors required to make well informed business decision. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. Our data has been culled out by our team of experts who have curated the report, considering market-relevant information. This report provides latest insights about the markets drivers, restraints, opportunities, and trends. It also discusses the growth and trends of various segments and the market in various regions.

Request Free Sample Report of Nanomedicine Market Report @ https://dataintelo.com/request-sample/?reportId=81345

Nanomedicine Market Report Includes:

For More Information on This Report Visit @ https://dataintelo.com/enquiry-before-buying/?reportId=81345

By Product Types:Quantum dotsNanoparticlesNanoshellsNanotubesNanodevices

The report is further broken down into various segments such as product types, applications, and regions.

By Applications:Segmentation encompasses oncologyInfectious diseasesCardiologyOrthopedicsOthers

Our analysts drafted the report by gathering information through primary (through surveys and interviews) and secondary (included industry body databases, reputable paid sources, and trade journals) methods of data collection. The report encompasses an exhaustive qualitative and quantitative evaluation.

The study includes growth trends, micro- and macro-economic indicators, and regulations and governmental policies.

By Regions:Asia Pacific (China, Japan, India, and Rest of Asia Pacific)Europe (Germany, the UK, France, and Rest of Europe)North America (the US, Mexico, and Canada)Latin America (Brazil and Rest of Latin America)Middle East & Africa (GCC Countries and Rest of Middle East & Africa)

The Nanomedicine Market Report Covers the Following Companies:CombimatrixAblynxAbraxis BioscienceCelgeneMallinckrodtArrowhead ResearchGE HealthcareMerckPfizerNanosphereEpeius BiotechnologiesCytimmune SciencesNanospectra Biosciences

The subject matter experts analyzed various companies to understand the products and/services relevant to the market. The report includes information such as gross revenue, production and consumption, average product price, and market shares of key players. Other factors such as competitive analysis and trends, mergers & acquisitions, and expansion strategies have been included in the report. This will enable the existing competitors and new entrants understand the competitive scenario to plan future strategies.

To Purchase This Report: https://dataintelo.com/checkout/?reportId=81345

The Report Provides:

The Nanomedicine Market Report Addresses the Following Queries:

For Best Discount on Purchasing this Report Visit https://dataintelo.com/ask-for-discount/?reportId=81345

About DataIntelo:DATAINTELO has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info: Name: Alex MathewsAddress: 500 East E Street, Ontario,CA 91764, United States.Phone No: USA: +1 909 545 6473 | IND: +91-7000061386Email: [emailprotected]Website: https://dataintelo.com

Here is the original post:
Nanomedicine Market Analysis With Key Players, Applications, Trends And Forecasts To 2026 - The Scarlet

AMR has recently added a new study titled Nanomedicine in theirs extensive and huge report catalog. This market intelligence research encapsulates vital details about the market flow as well as future status during the mentioned forecast period of 2025.

The Nanomedicine market size is predicted to witness enormous growth projections during 2019 2025. The notable factors that are expected to contribute to the growth of the Nanomedicine market during the forecast period.

With the slowdown in world economic growth, the Nanomedicine industry has also suffered a certain impact, but still maintained a relatively optimistic growth, the past four years, Nanomedicine market size to maintain the average annual growth rate of 7 from (2014 Market size XXXX) million $ in 2014 to (2019 Market size XXXX) million $ in 2019, our analysts believe that in the next few years, Nanomedicine market size will be further expanded, we expect that by 2024, The market size of the Nanomedicine will reach (2024 Market size XXXX) million $.

This 122-page market study report Nanomedicine is based on comprehensive research of the entire Nanomedicine.

Find out more about of the Nanomedicine market report at: https://www.amplemarketreports.com/report/global-nanomedicine-market-772150.html

This report offers up-to-date multiple market data on the tangible market situation and future outlook for the Nanomedicine.

This market report renders historical market data for 2013 2018, and forecasts from 2019 till 2025.

The study also targets essential aspects such as the latest trends, market drivers, challenges, and opportunities associated with the growth of producers in the global market for Nanomedicine.

This Report covers the manufacturers data, including: shipment, price, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the competitors better. This report also covers all the regions and countries of the world, which shows a regional development status, including market size, volume and value, as well as price data.

Principal Manufacturers Analysis on the Nanomedicine market included in this report:

The report also provides extensive profiles of the principal players across the globe in the Nanomedicine market as follows,

GE Healthcare, Mallinckrodt plc, Nanosphere Inc., Pfizer Inc., Merck & Co Inc., Celgene Corporation, CombiMatrix Corporation, Abbott Laboratories

With important details on companies Portfolio, sales, strategies, and the latest developments with their decisions are likely to affect the market share during the forecast period. Along with these market insights, the study presents the readers important insights into the tactics performed by principal companies to remain in the top/lead of this competing market.

Get sample copy of this Report with more info on Key Players, Application, Type and Regions in your email box https://www.amplemarketreports.com/sample-request/global-nanomedicine-market-772150.html

Application Analysis on the Nanomedicine market:

The report encloses a deep study on the Application of the Nanomedicine market with size in terms of both value, volume, sales and more.

The report presents precise insight on Application into current and future evolutions of the Nanomedicine market.

Gross Margin, Sales, Market share, Growth, and much more aspects.

Application of the Nanomedicine divided by considering number of parameters along with end user usage and importance.

Regional Segment Analysis on the Nanomedicine market:

Extensive analysis has been prepared on distribution/supply, revenue/pricing, and demand with the effectiveness of the Nanomedicine.

Furthermore, It also provides a deep and thorough evaluation of the distribution channel and technique of the distribution.

The report also details the newest information about the Nanomedicine production, supply, and allocation by major corporations around the globe by focusing below the number of regions as,

North America Country (United States, Canada), South America, Asia Country (China, Japan, India, Korea), Europe Country (Germany, UK, France, Italy), Other Country (Middle East, Africa, GCC)

The Report Helps Answer the Following Questions:

Inquire more on Discounts or if any questions before the purchase of this report https://www.amplemarketreports.com/enquiry-before-buy/global-nanomedicine-market-772150.html

With the given market data, Research on Global Markets offers customizations according to specific needs.

AMR is a leading market research player that offers Professional market research reports and custom research across multi geographies and industry verticals.

AMR delivers an extensive array of cutting-edge analysis solutions that help organizations, corporations, institutions, and individuals in building more solid decisions of the business to business needs.

About Us

Ample Market Research provides comprehensive market research services and solutions across various industry verticals and helps businesses perform exceptionally well. Our end goal is to provide quality market research and consulting services to customers and add maximum value to businesses worldwide. We desire to delivery reports that have the perfect concoction of useful data. Our mission is to capture every aspect of the market and offer businesses a document that makes solid grounds for crucial decision making.

Contact Address:

William James

Media & Marketing Manager

Call: +1 (530) 868 6979

Email: sales@amplemarketreports.com

Address: 3680 Wilshire Blvd, Ste P04 1387 Los Angeles, CA 90010

https://www.amplemarketreports.com

I am Mel Villarreal and Im passionate about business and finance news with over 4 years in the industry starting as a writer working my way up into senior positions.

Follow this link:
Revenue Growth of the Nanomedicine Market to be Influenced by Growing End-use Adoption - News Cast Report

Transferring this new technology in three branches:

Maturing the project from 2012 (8 years), in the right place and at the right time our nanoformulations started to navigate the medical evolution landscape in three challenge areas of (1) ZPH antibiotics innovation, (2) ZPH anti-cancer drugs, (3) and uncovering opportunities of a new ZPH nano-formulation against HIV/infectious diseases.

For each of these directions, the synthesis design was modified smartly (the key of success!). This remarkably refers to the obedience of our nanoformulation for an on-demand modification, and its very powerful medical potentials per se. Then, what we create is truly a multi-functional nanoplatform!

Nanomedicine & Nanodrugs ZPH can use the knowledge obtained in the development of antibiotics, anti-cancers (till now against 8 cancer cell lines) and anti-HIVs for drug development in other areas of diseases. Since there should be still hidden potentials for such a powerful nano-formulation design for more big successes, as well, that should be bravely tested. For example; brain cancer, pancreas cancer, etc., which have shown only small gains in survival with current drugs.

This nano-formulation is like this expression: Wie ein Held zum Siegen! (Symphony No.9, Op.125)

Continued here:
Nanomedicine & Nanodrugs ZPH | Nanomedicinezph.com

Theglobal nanomedical marketwas valued at $134.4 billion in 2016. This market is projected to grow at a compound annual growth rate (CAGR) of 14.0% from 2017-2022, and should reach $293.1 billion by 2022 from $151.9 billion in 2017.

Request For Report[emailprotected]https://www.trendsmarketresearch.com/report/sample/12261

Report Scope:

This report discusses the implications of technology and commercial trends in the context of the current size and growth of the pharmaceutical market, both in global terms and analyzed by the most important national markets. The important technologies supporting nanomedicine are reviewed, and the nature and structure of the nanomedicine industry are discussed with profiles of the leading 60+ companies, including recent merger and acquisition (M&A) activity. Five-year sales forecasts are provided for the national markets including the major therapeutic categories of products involved. Specific product categories quantified include diagnostics, cancer, CNS, anti-infective agents, cardiovasculars and anti-inflammatories.

Report Includes:

An overview of the global markets for nanotechnology used in medical applications Analyses of global market trends, with data from 2016, estimates for 2017, and projections of compound annual growth rates (CAGRs) through 2022 A review of technologies involved, in-depth analysis of applications in practice, and evaluation of future or potential applications Information on many significant products in which the nano dimension has made a significant contribution to product effectiveness A look at the regulatory environment, healthcare policies, demographics, and other factors that directly affect nanotechnology used in medicine Analysis of the markets dynamics, specifically growth drivers, inhibitors, and opportunities Coverage of strategies employed by companies specializing in nanomedicine to meet the challenges of this highly competitive market

Get Complete TOC with Tables and [emailprotected]https://www.trendsmarketresearch.com/report/discount/12261

Summary

Nano-enabled medical products began appearing on the market over a decade ago, and some have become best-sellers in their therapeutic categories. The principal areas in which nanomedical products have made an impact are cancer, CNS diseases, cardiovascular disease and infection control. The Summary Table gives estimates of the historical and current markets for these nanomedicine areas with a forecast through 2022.

The U.S. market is by far the largest in the global nanomedicine market and is set to continue to dominate the world marketplace; however, other national markets are expected to increase their shares over the next five years.

Reasons for Doing the Study

Nanomedicine is already an established market. Unlike some other potential applications of nanotechnology, which are still largely experimental, nanomedicine has already produced some significant products in which the nano dimension has made a significant contribution to product effectiveness. Now that aspects of the nanomedicine market are established, it is appropriate to review the technology, see its practical applications so far, evaluate the participating companies and look to its future.

<<< Get COVID-19 Report Analysis >>>https://www.trendsmarketresearch.com/report/covid-19-analysis/12261

View post:
Nanotechnology In Medical Applications Market To Eyewitness Massive Growth Trends Market Research 2017 to 2022 - Scientect

Healthcare Nanotechnology Market 2020 Research Report provides Emerging Market trends, Market Segmentation, regional outlook and comprehensive analysis on different market segments. It also provides key analysis on the market status of the Healthcare Nanotechnology manufacturers with best facts and figures, meaning, definition, SWOT analysis, expert opinions and the latest developments across the globe.This report also studies the global market competition landscape, market drivers and trends, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porters Five Forces Analysis.

COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.

Final Report will add the analysis of the impact of COVID-19 on this industry.

TO UNDERSTAND HOW COVID-19 IMPACT IS COVERED IN THIS REPORT REQUEST SAMPLE

Short Description About Healthcare Nanotechnology Market :

It is defined as the study of controlling, manipulating and creating systems based on their atomic or molecular specifications. As stated by the US National Science and Technology Council, the essence of nanotechnology is the ability to manipulate matters at atomic, molecular and supra-molecular levels for creation of newer structures and devices. Generally, this science deals with structures sized between 1 to 100 nanometer (nm) in at least one dimension and involves in modulation and fabrication of nanomaterials and nanodevices.

Get a Sample PDF of reporthttps://www.360researchreports.com/enquiry/request-sample/13841588

The research covers the current Healthcare Nanotechnology market size of the market and its growth rates based on 5-year records with company outline ofKey players/manufacturers:

Scope of the Healthcare Nanotechnology Market Report:

Nanotechnology is becoming a crucial driving force behind innovation in medicine and healthcare, with a range of advances including nanoscale therapeutics, biosensors, implantable devices, drug delivery systems, and imaging technologies.

The classification of Healthcare Nanotechnology includes Nanomedicine, Nano Medical Devices, Nano Diagnosis and Other product. And the sales proportion of Nanomedicine in 2017 is about 86.5%, and the proportion is in increasing trend from 2013 to 2017.

The global Healthcare Nanotechnology market is valued at 160800 million USD in 2018 and is expected to reach 255500 million USD by the end of 2024, growing at a CAGR of 9.7% between 2019 and 2024.

The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.

North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Healthcare Nanotechnology.

Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%.

This report studies the Healthcare Nanotechnology market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Healthcare Nanotechnology market by product type and applications/end industries.

Get a Sample Copy of the Healthcare Nanotechnology Market Report 2020

Report further studies the market development status and future Healthcare Nanotechnology Market trend across the world. Also, it splits Healthcare Nanotechnology market Segmentation by Type and by Applications to fully and deeply research and reveal market profile and prospects.

Major Classifications are as follows:

Major Applications are as follows:

Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth Rate of Healthcare Nanotechnology in these regions, from 2014 to 2024, covering

This Healthcare Nanotechnology Market Research/Analysis Report Contains Answers to your following Questions

Inquire more and share questions if any before the purchase on this report at https://www.360researchreports.com/enquiry/pre-order-enquiry/13841588

Major Points from Table of Contents:

1. Market Overview1.1 Healthcare Nanotechnology Introduction1.2 Market Analysis by Type1.3 Market Analysis by Applications1.4 Market Dynamics1.4.1 Market Opportunities1.4.2 Market Risk1.4.3 Market Driving Force

2.Manufacturers Profiles

2.4.1 Business Overview2.4.2 Healthcare Nanotechnology Type and Applications2.4.2.1 Product A2.4.2.2 Product B

3.Global Healthcare Nanotechnology Sales, Revenue, Market Share and Competition By Manufacturer (2019-2020)

3.1 Global Healthcare Nanotechnology Sales and Market Share by Manufacturer (2019-2020)3.2 Global Healthcare Nanotechnology Revenue and Market Share by Manufacturer (2019-2020)3.3 Market Concentration Rates3.3.1 Top 3 Healthcare Nanotechnology Manufacturer Market Share in 20203.3.2 Top 6 Healthcare Nanotechnology Manufacturer Market Share in 20203.4 Market Competition Trend

4.Global Healthcare Nanotechnology Market Analysis by Regions

4.1 Global Healthcare Nanotechnology Sales, Revenue and Market Share by Regions4.1.1 Global Healthcare Nanotechnology Sales and Market Share by Regions (2014-2019)4.1.2 Global Healthcare Nanotechnology Revenue and Market Share by Regions (2014-2019)4.2 North America Healthcare Nanotechnology Sales and Growth Rate (2014-2019)4.3 Europe Healthcare Nanotechnology Sales and Growth Rate (2014-2019)4.4 Asia-Pacific Healthcare Nanotechnology Sales and Growth Rate (2014-2019)4.6 South America Healthcare Nanotechnology Sales and Growth Rate (2014-2019)4.6 Middle East and Africa Healthcare Nanotechnology Sales and Growth Rate (2014-2019)

5.Healthcare Nanotechnology Market Forecast (2020-2024)5.1 Global Healthcare Nanotechnology Sales, Revenue and Growth Rate (2020-2024)5.2 Healthcare Nanotechnology Market Forecast by Regions (2020-2024)5.3 Healthcare Nanotechnology Market Forecast by Type (2020-2024)5.3.1 Global Healthcare Nanotechnology Sales Forecast by Type (2020-2024)5.3.2 Global Healthcare Nanotechnology Market Share Forecast by Type (2020-2024)5.4 Healthcare Nanotechnology Market Forecast by Application (2020-2024)5.4.1 Global Healthcare Nanotechnology Sales Forecast by Application (2020-2024)5.4.2 Global Healthcare Nanotechnology Market Share Forecast by Application (2020-2024)

6.Sales Channel, Distributors, Traders and Dealers6.1 Sales Channel6.1.1 Direct Marketing6.1.2 Indirect Marketing6.1.3 Marketing Channel Future Trend6.2 Distributors, Traders and Dealers

7.Research Findings and Conclusion

8.Appendix8.1 Methodology8.2 Data Source

Continued..

Purchase this report (Price3480 USD for a single-user license) https://www.360researchreports.com/purchase/13841588

About Us:

360 Research Reports is the credible source for gaining the market reports that will provide you with the lead your business needs. At 360 Research Reports, our objective is providing a platform for many top-notch market research firms worldwide to publish their research reports, as well as helping the decision makers in finding most suitable market research solutions under one roof. Our aim is to provide the best solution that matches the exact customer requirements. This drives us to provide you with custom or syndicated research reports.

Contact Us:Name: Mr. Ajay MoreEmail: [emailprotected]Organization: 360 Research ReportsPhone: +44 20 3239 8187/ +14242530807

For More Related Reports Click Here :

Data Center Busway Market Share 2020 : Top Countries Data, Defination, Business Opportunity, SWOT Analysis, Applications, Trends and Forecast to 2026

Turbo Molecular Pumps Market Size 2020 Global Industry Brief Analysis by Top Countries Data, Market Share, Defination, Industry Trends, News and significant Growth With Regional Trends By Forecast 2026

Metal Casting Robots Market Size 2020 : Top Countries Data, Market Share, Growth Opportunities, Defination, Emerging Technologies, Trends,Growth, Segments, Landscape and Demand by Forecast to 2026

View original post here:
Healthcare Nanotechnology Market 2020 : Industry Outlook with Top Countries Data, Market Share, Growth Analysis, Opportunities and Forecast To 2024 -...

There is a continuous growth in Healthcare Nanotechnology (Nanomedicine) Market in last five years and also continue for the forecast year 2023. Healthcare Nanotechnology (Nanomedicine) industry report analyses the outline of the global market with respect to major regions and segmented by types and applications. Healthcare Nanotechnology (Nanomedicine) Market covers top manufacturers, product scope, market overview, market opportunities, market risk, market driving force, technological advancement, distributors, traders, dealers, research findings.

Get a Sample Copy Of The Report At https://www.absolutereports.com/enquiry/request-sample/13102426

The global healthcare nanotechnology market is expected to witness a CAGR of 15.1%. North America currently dominates the market, and is expected to maintain its position over the forecasted period.

Rising Applications in Oncology

Nanomedicine is a promising mode of cancer treatment. With the advantage of the properties of matter at nanoscale, nanomedicine promises to develop innovative drugs with greater efficacy and lesser side effects than standard therapies. Nanoscale objects are used by themselves or as parts of larger devices containing multiple nanoscale objects. It has the potential to change the current methods of diagnosing and treating cancer. Translation of nano-based cancer therapies and diagnostics has witnessed significant progress and several more developments are in the pipeline. The increasing incidence of cancer and importance of nanomedicine in modern cancer treatment procedures, are expected to drive the demand for nanomedicines during the forecast period.The other factors includes increasing incidence of cardiovascular diseases, increasing research funding and rising awareness of nanomedicine application.

High Costs of Nanotechnology-Based Medical Devices

Cost is the main factor that is often overlooked, which is specifically important in the face of ever increasing healthcare cost and unpredictable reimbursement environment. There are several FDA approved nanoparticle-based products in the market, which can be compared with their non-nanoparticle based counterparts. Although these formulations may be more efficient and less toxic than their counterparts, their costs may also be significantly high. The average cost per dose of anticancer drug doxorubicin is about USD 62-162, compared to USD 5,594 for Doxil, which is a nanoparticle containing doxorubicin. Therefore, owing to the inability of the industry to find a cost-effective method of scaling up the production, the cost of nanomedicine therapies is likely to remain high over the forecast period. This high cost of nanoparticle-assisted medicine is hindering the growth of the market. The other restraining factor also include time-consuming product approval.

US Dominates the Market

Geographically, the United States currently dominates the market, and is expected to maintain its position over the forecast period. In addition to the booming R&D activities, the United States has also initiated several measures in the recent times, to advance and develop the nanotechnology applications in the healthcare sector. Owing to the large geriatric population, growing need for diagnostics and augmented cancer therapies, government initiatives, and rising awareness of nanomedicines, the US healthcare nanotechnology sector is expected to witness a substantial growth during the forecast period.

Major Players in the Market

The Major Players are ABBOTT LABORATORIES, COMBIMATRIX CORPORATION, GE HEALTHCARE, SIGMA-TAU PHARMACEUTICALS INC., JOHNSON & JOHNSON, MALLINCKRODT PLC, MERCK & COMPANY INC., NANOSPHERE INC., PFIZER, INC. AND CELGENE CORPORATION amongst others.

Major Regions: US,Canada,Mexico,France,UK,Germany,Italy,Spain,Rest of Europe,India,China,Japan,Australia,Japan,Rest of APAC,GCC,South Africa,Rest of Middle East and Africa,Brazil,Argentina,Rest of South America

Inquire Or Share Your Questions If Any Before The Purchasing This Report https://www.absolutereports.com/enquiry/pre-order-enquiry/13102426

Reasons to Purchase this Report:

Major Points Covered in Table of Content of Healthcare Nanotechnology (Nanomedicine) Market forecast 2023

1. Introduction of Healthcare Nanotechnology (Nanomedicine) Market Report

1.1 Study Deliverables

1.2 General Study Assumptions

2. Research Methodology

2.1 Introduction

2.2 Analysis Methodology

2.3 Study Phases

2.4 Econometric Modelling

3. Executive Summary

4. Market Overview and Healthcare Nanotechnology (Nanomedicine) Market Trends

4.1 Introduction

4.2 Market Trends

4.3 Porters Five Force Framework

4.3.1 Bargaining Power of Suppliers

4.3.2 Bargaining Power of Consumers

4.3.3 Threat of New Entrants

4.3.4 Threat of Substitute Products and Services

4.3.5 Competitive Rivalry within the Industry

5. Healthcare Nanotechnology (Nanomedicine) Market Dynamics

5.1 Drivers

5.2 Restraints

5.3 Opportunities

6.Global Healthcare Nanotechnology (Nanomedicine) Market, Segmented by Size

7. Global Healthcare Nanotechnology (Nanomedicine) Market, Segmented by Technology Type

Purchase This Report (Price 4250 USD for single user license) https://www.absolutereports.com/purchase/13102426

8. Global Healthcare Nanotechnology (Nanomedicine) Market, Segmented by Geography

8.1 North America

8.1.1 United States

8.1.2 Canada

8.1.3 Mexico

8.1.4 Others

8.2 South America

8.2.1 Brazil

8.2.2 Argentina

8.2.3 Others

8.3 Asia-Pacific

8.3.1 China

8.3.2 Japan

8.3.3 India

8.3.4 Others

8.4 Europe

8.4.1 United Kingdom

8.4.2 Germany

8.4.3 France

8.4.4 Others

8.5 Africa and Middle East

8.5.1 UAE

8.5.2 South Africa

8.5.3 Saudi Arabia

8.5.4 Others

9. Competitive Landscape

9.1 Introduction

9.2 Market Share Analysis

9.3 Developments of Key Players

10. Key Vendor Analysis (Overview, Products & Services, Strategies)

11. Future Outlook of the Market

12. Disclaimer

And Many More.

For Detail TOC Click Here

About Absolute Reports:

Absolute Reports is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in depth market research. We are one of the top report resellers in the market, dedicated towards bringing you an ingenious concoction of data parameters.

Contact Info:

Name: Ajay More

Email: [emailprotected]

Organization: Absolute Reports

Phone: +14242530807/+44203239 8187

Our Other report :Glass Bubbles Market 2020 Analysis Manufacturing Cost Structure, Industry Chain Structure, Raw Material and Suppliers Opportunities & Future Potential 2024

Automotive Part Cleaners & Degreasers Market 2020 Research Analysis by Product Overview and Scope and Suppression Systems Forecasts 2024

Flux Removers Market 2020 Structure, Research Methodology Forecast to 2024

2-Methyl-Propenoic Acid Market 2020 Report Presents an Overall Analysis, Development Trends, Driving Forces, Opportunities & Future Potential 2024

Global Heavy Duty Casters Market 2020 Segmented by Application and Geography Trends, Growth and Forecasts to 2026

Product Type Coverage of Global Solid Bleached Board Market by Market Size & Forecast, Major Company of Product Type 2020-2026

Global Monobutylamine (MMA) Market 2020 Size, Share, Growth, Trends and Forecast 2026, Business Opportunities and Future Investments

Ready to Assemble Furnitures Market Overview, Industry Top Manufactures, Market Size, Industry Growth Analysis & Forecast: 2026

Global Swept Frequency Capacitive Sensing Market2020Production, Revenue, Price and Gross Margin Analysis with Forecasts to 2026

Global Grape Seed Oil Market 2020 Size, Share, Growth, Trends and Forecast 2024, Business Opportunities and Future Investments

Global Reusable Container Market Share, Growth, Trend Analysis and Forecast from 2020-2026; Consumption Capacity by Volume and Production Value

Read the original post:
Global Healthcare Nanotechnology (Nanomedicine) Market 2020 |Size, Trends, Comprehensive Research Study, Development Status, Opportunities, Future...

The global Nanomedicine market report is a comprehensive research that focuses on the overall consumption structure, Demand, Revenue and Forecast till 2026. The report focuses on key companies in the global Nanomedicine industry, market segments, competition, and the growth drivers, constraints and SWOT analysis. This report focuses on Nanomedicine volume and value at the global level, regional level and company level.

(Get up to 20% discount on this)

Request for sample:

https://www.marketinsightsreports.com/reports/07212156415/global-nanomedicine-market-size-status-and-forecast-2020-2026/inquiry?Mode=52

Nanomedicine Market will research at CAGR of 13.5% during the Forecast Period 2017 to 2025.

The Report includestop leading companies Combimatrix, Ablynx, Abraxis Bioscience, Celgene, Mallinckrodt, Arrowhead Research, GE Healthcare, Merck, Pfizer, Nanosphere, Epeius Biotechnologies, Cytimmune Sciences, Nanospectra Biosciences

Global Nanomedicine Market, By Type

Quantum dots

Nanoparticles

Nanoshells

Nanotubes

Nanodevices

Global Nanomedicine Market, By Application

oncology

Infectious diseases

Cardiology

Orthopedics

Others

Key Market Trends

Neurological Diseases is Expected to Show Better Growth in the Forecast Period

A large number of brain disorders with neurological and psychological conditions result in short-term and long-term disabilities. The Parkinsons Foundation Prevalence Project estimates that 930,000 people in the United States will be living with Parkinson Disease (PD) by the year 2020. This number is predicted to rise to 1.2 million by 2030. Therefore recent years has observed a significant number of research studies being published on methods for the synthesis of nanoparticle-encapsulated drugs within in vivo and in vitro studies. The insufficient absorbance of oral drugs administered for a range of neurological conditions, such as Alzheimers disease, Parkinson disease, tumor, neuro-AIDS, among others,

North America is Expected to Hold the Largest Share of the Market

In the United States, several companies are closely observing the developments in nanostructured materials across various applications in the healthcare industry, including medical devices, to improve efficiency and efficacy.

For instance, nano-manufacturing in Small Business Innovation Research (SBIR) programs was developed for both commercial and public use. Companies are targeting the treatment of several cancer types and infectious diseases through immunotherapy, where nanoemulsion vaccines and drugs play a significant role. In the United States, one of the major challenges associated with nanotechnology is the ability to integrate nanoscale materials into new devices and systems, along with an application of novel properties at the nano-level. Furthermore, most of the companies are investing in R&D. Nanotechnology is thus likely to play a significant role in the delivery of drugs, which is expected to further advance the research and development activities, over the forecast period.

Global Nanomedicine Market Segmentation by Region:

North America, United States, Canada, Mexico, Asia-Pacific, China, India, Japan, South Korea, Australia, Indonesia, Malaysia, Philippines, Thailand, Vietnam, Europe, Germany, France, UK, Italy, Russia, Rest of Europe, Central & South America

Table of Contents:

Report Overview:It includes Nanomedicine market study scope, players covered, key market segments, market analysis by application, market analysis by type, and other chapters that give an overview of the research study.

Executive Summary:This section of the report gives information about Nanomedicine market trends and shares market size analysis by region and analysis of global market size. Under market size analysis by region, analysis of market share and growth rate by region is provided.

Profiles of International Players:Here, key players of the Nanomedicine market are studied on the basis of gross margin, price, revenue, corporate sales, and production. This section gives a business overview of the players and shares their important company details.

Regional Study:All of the regions and countries analyzed in the Nanomedicine market report is studied on the basis of the market size by application, the market size by product, key players, and market forecast.

Key Players:This part of the Nanomedicine market report discusses expansion plans of companies, key mergers and acquisitions, funding and investment analysis, company establishment dates, revenues of manufacturers, and their areas served and manufacturing bases.

Browse This Report:

https://www.marketinsightsreports.com/reports/07212156415/global-nanomedicine-market-size-status-and-forecast-2020-2026?Mode=52

Customization of the Report

The report could be customized according to the clients specific research requirements. No additional cost will be required to pay for limited additional research.

Marketinsightsreports are inspired to help our clients grow by providing business insight with our huge market intelligence repository.

Contact Us:

Irfan Tamboli (Head of Sales) Market Insights Reports

Phone: + 1704 266 3234

Mob: +91-750-707-8687

[emailprotected]

[emailprotected]

All the reports that we list have been tracking the impact of COVID-19 the market. Both upstream and downstream of the entire supply chain has been accounted for while doing this. Also, where possible, we will provide an additional COVID-19 update supplement/report to the report in Q3, please check for with the sales team

Follow this link:
Nanomedicine Market Competitive Research And Precise Outlook 2020 To 2026 - Cole of Duty

This article was originally published here

Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2020 Jul 22:e1654. doi: 10.1002/wnan.1654. Online ahead of print.

ABSTRACT

Lung cancer is considered to cause the most cancer-related deaths worldwide. Due to the deficiency in early-stage diagnostics and local invasion or distant metastasis, the first line of treatment for most patients unsuitable for surgery is chemotherapy, targeted therapy or immunotherapy. Nanocarriers with the function of improving drug solubility, in vivo stability, drug distribution in the body, and sustained and targeted delivery, can effectively improve the effect of drug treatment and reduce toxic and side effects, and have been used in clinical treatment for lung cancer and many types of cancers. Here, we review nanoparticle (NP) formulation for lung cancer treatment including liposomes, polymers, and inorganic NPs via systemic and inhaled administration, and highlight the works of overcoming drug resistance and improving cancer immunotherapy. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease.

PMID:32700465 | DOI:10.1002/wnan.1654

See more here:
Nanomedicine in lung cancer: Current states of overcoming drug resistance and improving cancer immunotherapy - DocWire News